Skip to main content

Peer Review reports

From: Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

Original Submission
18 Sep 2021 Submitted Original manuscript
8 Dec 2021 Reviewed Reviewer Report
4 May 2022 Reviewed Reviewer Report
15 Oct 2022 Author responded Author comments - Mohammed Fasihul Alam
23 Oct 2022 Author responded Author comments - Mohammed Fasihul Alam
Resubmission - Version 2
15 Oct 2022 Submitted Manuscript version 2
26 Oct 2022 Author responded Author comments - Mohammed Fasihul Alam
Resubmission - Version 3
26 Oct 2022 Submitted Manuscript version 3
30 Oct 2022 Reviewed Reviewer Report
23 Dec 2022 Reviewed Reviewer Report
4 Feb 2023 Author responded Author comments - Mohammed Fasihul Alam
Resubmission - Version 4
4 Feb 2023 Submitted Manuscript version 4
11 Feb 2023 Reviewed Reviewer Report
14 Feb 2023 Reviewed Reviewer Report
26 Feb 2023 Author responded Author comments - Mohammed Fasihul Alam
Resubmission - Version 5
26 Feb 2023 Submitted Manuscript version 5
Publishing
1 Mar 2023 Editorially accepted
8 Mar 2023 Article published 10.1186/s12913-023-09233-w

You can find further information about peer review here.

Back to article page